Condition
    Limited
    Effectiveness 3/5

    Omega-3 Fatty Acids for Psoriasis

    Omega-3 monotherapy for psoriasis has produced inconsistent results across trials. The clearer signals come from studies combining omega-3 with conventional therapy, and from the cardiometabolic benefit relevant to psoriasis comorbidity.

    Overview

    Omega-3 monotherapy for psoriasis has produced inconsistent results across trials. The clearer signals come from studies combining omega-3 with conventional therapy, and from the cardiometabolic benefit relevant to psoriasis comorbidity.

    Verdict

    Insufficient evidence

    Two meta-analyses found fish oil on its own does not reduce psoriasis severity. There is some signal that omega-3 alongside conventional therapy improves PASI, and it helps the cardiometabolic risks that travel with psoriasis, but it is not a standalone treatment.

    How It Works

    Psoriasis is driven by the IL-23/Th17 axis, with keratinocyte hyperproliferation downstream of that immune activation. Omega-3 fatty acids reduce leukotriene B4, a chemoattractant found at high levels in psoriatic plaques, and generate resolvins that dampen neutrophil recruitment. The limitation is that this touches the inflammatory periphery rather than the central Th17 driver, which is what modern biologics target directly. That mismatch is a reasonable explanation for why omega-3 produces at most modest changes in plaque severity.

    Dosing & Protocol

    Typical dose

    Recommended dose
    2000-4000mg EPA+DHA daily
    Expected timeframe
    Not established

    Protocol

    form
    Not applicable
    duration
    Not applicable
    co factor
    Evidence is insufficient: trials of oral fish oil in psoriasis at 1.8-5 g/day EPA+DHA give conflicting results, with several well-conducted studies finding no significant improvement in PASI. Intravenous omega-3 showed benefit in one hospital study, which does not translate to capsules. Topical therapy, phototherapy and systemic or biologic treatment carry the evidence.
    titration
    Not applicable
    starting dose
    Not applicable as an established treatment

    Evidence

    What the studies say

    Randomised trials of oral omega-3 in plaque psoriasis have produced conflicting results: some report reductions in PASI scores, erythema and scaling, while others show no difference from placebo. Trials of intravenous omega-3 lipid emulsions in acute guttate psoriasis have shown more consistent short-term benefit, but that route is not comparable to supplementation. Studies adding omega-3 to conventional treatment more often report additive improvement than monotherapy trials do. Given the strong association between psoriasis and cardiovascular and metabolic disease, omega-3 has a defensible supporting role for comorbidity management even where skin effects are uncertain. It should not delay effective topical, phototherapy or systemic treatment.

    Efficacy of fish oil and its components in the management of psoriasis: a systematic review of 18 randomized controlled trials

    Score: 8/10
    2020
    systematic_review
    n=927

    Chen X, Hong S, Sun X +9 more

    Fish oil or ω-3 PUFAs combined with conventional treatments, however, resulted in a decreased PASI score (mean difference [MD], -3.92; 95%CI, -6.15 to -1.69; P = 0.0006) and lesion area.

    View source

    Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: a randomized control clinical trial

    Score: 6/10
    2014
    rct
    n=44

    Guida B, Napoleone A, Trio R +4 more

    Specifically Psoriasis Area Score Index (7.7 ± 3.7, 5.3 ± 4.3 and 2.6 ± 3.0, respectively; p < 0.05), itch scores and Dermatological Life Quality Index all decreased respect to baseline.

    View source

    Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials

    Score: 8/10
    2019
    meta_analysis
    n=625

    Yang SJ, Chi CC

    The current evidence does not support the use of fish oil supplement in treating psoriasis.

    View source

    Safety

    Caveats

    Untreated psoriasis carries joint and cardiometabolic risk - do not delay dermatological treatment. Safety ceiling: below 3 g/day EPA+DHA without supervision; higher raises bleeding risk with anticoagulants and antiplatelets and should be stopped before surgery. Methotrexate and biologic patients should tell their team about any supplement. Standard doses acceptable in pregnancy; avoid cod liver oil because of vitamin A, which interacts with acitretin and other retinoids.

    Less likely to help if

    People with moderate to severe plaque psoriasis or psoriatic arthritis, who need systemic therapy.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.